Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 102

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 102
---
 President, Commercial Strategy & Portfolio Management. From October 2020 until December 2020, he served as our Interim Chief Commercial Officer and Vice President, Commercial Strategy and Portfolio Management. From December 2020 until November 2021, Mr. Murray served as our Senior Vice President, Chief Commercial Officer. Mr. Murray was promoted to Executive Vice President, Chief Customer Officer in November 2021, and was designated by the Board as an executive officer in April 2024.

Mr. Murray's equity awards are subject to clawback under circumstances set forth in the Company’s clawback policy. Mr. Murray's salary, bonus and other compensation is reviewed and updated by our compensation committee on an annual basis. For the details of his 2024 salary, bonus and other compensation, see the disclosure provided under “2024 Named Executive Officer Compensation.”

Ryan E. Brown – Former Executive Vice President, General Counsel and Corporate Secretary

On February 25, 2018, we hired Ryan Brown as our Vice President, Global Chief Compliance Officer and Regulatory Counsel. On February 19, 2021, Mr. Brown was appointed as our Senior Vice President, General Counsel. Mr. Brown was promoted to Executive Vice President, General Counsel in February 2023.

On November 24, 2024, Ryan Brown informed the Company of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024. Mr. Brown remained as a non-executive employee of the Company until March 24, 2025 to support the transition of our new Chief General Counsel.

Post-Employment Benefits and Change in Control Arrangements for the Company’s Named Executive Officers

Change in Control and Severance Agreements – Messrs. Arif, Estepan and Murray and Dr. Rodino-Klapac

During 2024, we were a party to our standard Executive Change in Control and Severance Agreement, which was most recently revised in 2019 (the “2019 CIC Agreements"), with each of Messrs. Arif, Estepan and Murray and Dr. Rodino-Klapac. Under the 2019 CIC Agreement, if an executive experiences a “constructive termination” or termination by the Company other than for “cause” (as each term is defined below) during the 12-month period following a “change in control” (as defined in the CIC Agreement), and if the executive delivers to the Company a general